NCT07593690Not yet recruitingPhase 1
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HW241045 Tablets After Single and Multiple Dosing in Healthy Study Participants.
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.1 site in 1 country102 target enrollmentStarted: June 1, 2026Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 102
- Locations
- 1
Study Overview
Brief Summary
This is a Phase I, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and food effect (FE) of HW241045 in healthy participants.
This study consists of three parts:1）Part A: A single-dose, two-period, two-way crossover design to evaluate the safety and pharmacokinetic differences between Formulation A and Formulation B of HW241045 tablets; 2）Part B: A single-dose ascending dose design to evaluate the safety, tolerability, and pharmacokinetic profiles of HW241045 Formulation B following single administration. A food-effect study is nested within this part.3）Part C: A multiple-dose ascending dose design to evaluate the safety, tolerability, and pharmacokinetic profiles of HW241045 Formulation B after multiple administrations.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •The study participant is able to communicate well with the investigator, understand and comply with all requirements of the study, fully comprehend the purpose, nature and methodology of the trial as well as potential adverse reactions, and sign the informed consent form prior to initiation of any study procedures.
- •Healthy male and female study participants aged 18 to 45 years (inclusive).
- •Female study participants shall have a body weight ≥ 45 kg, male study participants ≥ 50 kg; body mass index (BMI) ranges from 19 to 26 kg/m² (inclusive).
Exclusion Criteria
- •Any study participant with a past or current clinically severe or chronic disease involving the circulatory, endocrine, nervous, digestive, respiratory, hematologic, or immune system, as well as psychiatric disorders and metabolic abnormalities; or with any other disease deemed by the investigator likely to interfere with the trial results.
- •Participants with a history of gastrointestinal, hepatic or renal diseases that may affect drug absorption or metabolism, or with known or suspected diseases that may interfere with drug intake, transportation, absorption, distribution, metabolism or excretion.
- •Participants with a history of drug or food allergy, allergic diseases, or allergic constitution (allergic to two or more substances), or with a confirmed allergy to any component of the study drug.
- •Participants who have used any drugs that inhibit or induce hepatic drug metabolism within 30 days prior to the trial or during the trial period.
- •Participants with any other factors deemed unsuitable for participation in the clinical study by the investigator.
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Phase I Study of HW201877 in Healthy SubjectsNCT07373457Wuhan Humanwell Innovative Drug Research and Development Center Limited Company104
Recruiting
Phase 1
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese ParticipantsNCT07626515Hoffmann-La Roche36
Recruiting
Phase 1
A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis ParticipantsAtopic DermatitisNCT07488065Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.90
Recruiting
Phase 1
A First-in-Human Single and Multiple Ascending Dose Study of MT-251NCT07423299Mirador Therapeutics, Inc.70
Not yet recruiting
Phase 2
A Study on the Safety and Benefits of Probiotic Treatment for Women with Vaginal InfectionCTRI/2026/04/108493AceOne Rs120